Amsterdam, The Netherlands, 23 October 2018 – BioGX B.V. recently released 5 new sexual health CE Mark IVD tests, expanding BioGX’s CE-IVD menu to a total of 21 multiplex panels, with additional test panels to be released before the end of 2018.
Amsterdam, The Netherlands, 24 May 2018 – BioGX B.V. continues its *BD MAX menu expansion with the launch of six additional CE-Mark infectious disease tests on Becton, Dickinson and Company’s BD MAX Sample-to-Answer platform. This brings the company’s CE-Mark menu for the BD MAX to eleven tests, with an additional ten planned for the second half […]
BIRMINGHAM, Ala., Feb. 8, 2018 /PRNewswire/ — BioGX continues to expand its global presence with the announcement of a distribution partnership between BioGX’s Amsterdam-based European subsidiary, BioGX B.V., and U.K.-based distributor, Launch Diagnostics.
BIRMINGHAM, Ala., Feb. 6, 2018 /PRNewswire/ — BioGX continues to expand its international presence with the announcement of a new strategic partnership between BioGX’s Amsterdam-based European subsidiary and Switzerland-based distributor, AxonLab AG.
VIENNA, AUSTRIA, April 24, 2017 /PRNewswire/ — BioGX, a Birmingham Alabama based molecular diagnostics company, announced the launch of four additional CE-IVD infectious disease tests at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), reflecting the inspiring vision of ECCMID: “Managing Infections, Promoting Science”. BioGX has developed an extensive line of multiplex tests […]
BIRMINGHAM, Ala., April 21, 2017 /PRNewswire/ — BioGX, a developer and manufacturer of molecular diagnostics CE-IVD tests has announced the establishment of European operations based in Amsterdam, Netherlands.
BIRMINGHAM, Ala., November 10, 2016 — BioGX announced its Sample-Ready™ lyophilized qPCR technology was selected by the NASA WetLab-2 program to conduct genetic analysis aboard the International Space Station (ISS). BioGX core technology enables real-time PCR based scientific studies in the microgravity environment of the ISS.
BioGX announced it has received CE-IVD marking for its Flu A, Flu B, RSV automated test on Becton, Dickinson and Company’s (BD) BD MAXTM system for detection of Influenza A, B and Respiratory Syncytial Virus (RSV). The test is intended to simultaneously detect the presence of Flu A, Flu B and RSV RNA present in […]